Nitrolingual® Pumpspray (nitroglycerin lingual spray):
Effective, reliable, and ready for patients when they need it.
Nitroglycerin is an important part of angina therapy.
For patients with angina due to CAD, AHA/ACC/ACP treatment guidelines recommend the use of short-acting nitrates for acute relief and prophylaxis of angina pectoris.1
Treatment of angina patients may include: 2
"All patients with angina should receive a prescription for sublingual nitroglycerin and education about its proper use." 1
Patients should be educated that sublingual nitroglycerin is a short-acting drug so that they will not be reluctant to use it. 1
Exercise is important for cardiovascular health.
Exercise-based cardiac rehabilitation is associated with lower total and cardiac mortality rates compared to usual medical care. 3
Effects of Exercise-Based Cardiac Rehabilitation on Study End Points. 3
Guidelines for CAD treatment reinforce the importance of an exercise program for patients with stable angina pectoris. 1
"Virtually all patients with known coronary artery disease (CAD), if stable, should engage in regular physical activity." 4
But for some patients with CAD, exercise is a challenge…
Patient fear is a major barrier to exercise adherence following a cardiac event.
In a recent survey of patients who have previously experienced a cardiac event: 5
- 74% of patients expressed fear about exercise
- 85% of patients agreed that more patients would exercise if they knew their angina medication could be used as a preventive measure before exercise
Acute Relief and Preventive Action.
Nitrolingual® Pumpspray (nitroglycerin lingual spray) improves patients’ exercise tolerance, while addressing the acute symptoms of angina pectoris.6
In a dose-ranging study of patients who had previously experienced a cardiac event, Nitrolingual Pumpspray:
- Increased maximum exercise duration versus placebo spray (0.4 mg)
- Increased time-to-onset of clinically relevant ST-segment depression versus placebo spray (0.8 mg)
- Increased time-to-onset of angina versus placebo spray (0.4 mg)
1 American Heart Association. ACC/AHA/ACP-ASIM Guidelines for the management of patients with chronic stable angina: Executive summary and recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Circulation. 1999;99:2829-2848.
2 Mayo Clinic Staff. Angina. Mayo Clinic website. http://www.mayoclinic.com/health/angina/DS00994/DSECTION=treatments-and-drugs. Accessed October 18, 2011.
3 Franklin BA, et al. Cardiac rehabilitation and secondary prevention of coronary heart disease: An American Heart Association scientific statement from the Council on Clinical Cardiology and the Council on Nutrition, Physical Activity, and Metabolism, in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2005;111:369-376.
4 Thompson PD. Exercise prescription and proscription for patients with coronary artery disease. Circulation. 2005;112:2354-2363.
5 Data on file at Espero Pharmaceuticals.
6 Thadani U, Wittig T. A randomized, double-blind, placebo-controlled, crossover, dose-ranging multicenter study to determine the effect of sublingual nitroglycerin spray on exercise capacity in patients with chronic stable angina. Clinical Medicine Insights; Cardiology. 2012; 6:87-95.
Stability & Potency